Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Treace Medical Concepts (TMCI) Change in Receivables (2020 - 2025)

Treace Medical Concepts' Change in Receivables history spans 6 years, with the latest figure at $9.5 million for Q4 2025.

  • For Q4 2025, Change in Receivables fell 44.64% year-over-year to $9.5 million; the TTM value through Dec 2025 reached $2.1 million, down 63.25%, while the annual FY2025 figure was $2.1 million, 63.25% down from the prior year.
  • Change in Receivables reached $9.5 million in Q4 2025 per TMCI's latest filing, up from $2.6 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $17.2 million in Q4 2024 to a low of -$9.3 million in Q1 2025.
  • Average Change in Receivables over 5 years is $1.6 million, with a median of -$133000.0 recorded in 2022.
  • Peak YoY movement for Change in Receivables: plummeted 369.82% in 2021, then surged 343.49% in 2023.
  • A 5-year view of Change in Receivables shows it stood at $7.0 million in 2021, then surged by 59.14% to $11.1 million in 2022, then grew by 20.95% to $13.4 million in 2023, then grew by 28.09% to $17.2 million in 2024, then tumbled by 44.64% to $9.5 million in 2025.
  • Per Business Quant, the three most recent readings for TMCI's Change in Receivables are $9.5 million (Q4 2025), $2.6 million (Q3 2025), and -$696000.0 (Q2 2025).